Processa Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Mar 18, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 18, 2026
PCSA$1.87-4.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
| Years Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash Flows From Operating Activities | ||
| Net Loss | $(13,563,834) | $(11,850,118) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 1,204 | 782 |
| Non-cash lease expense for right-of-use assets | 70,677 | 87,184 |
| Unrealized gain on digital assets at fair value | (295,180) | - |
| Stock-based compensation | 857,550 | 629,514 |
| Net changes in operating assets and liabilities: | ||
| Prepaid expenses and other | 834,651 | (1,030,436) |
| Operating lease liability | (66,905) | (83,649) |
| Accounts payable | 175,916 | 569,263 |
| Due from related parties | - | (39) |
| Accrued expenses | 600,726 | 432,457 |
| Net cash used in operating activities | (11,385,195) | (11,245,042) |
| Cash Flows From Investing Activities | ||
| Purchase of digital asset | (850,000) | - |
| Purchase of equipment | - | (3,244) |
| Net cash used in investing activities | (850,000) | (3,244) |
| Cash Flows From Financing Activities | ||
| Net proceeds from issuance of common stock | 16,597,831 | 7,763,079 |
| Shares withheld to pay taxes on stock-based compensation | (10,404) | (15,902) |
| Settlement of stock award | - | (8,561) |
| Payment of finance lease obligation | (6,602) | (5,202) |
| Net cash provided by financing activities | 16,580,825 | 7,733,414 |
| Net Increase (Decrease) in Cash and Cash Equivalents | 4,345,630 | (3,514,872) |
| Cash and Cash Equivalents - Beginning of Year | 1,191,325 | 4,706,197 |
| Cash and Cash Equivalents - End of Year | $5,536,955 | $1,191,325 |
Consolidated Statements of Cash Flows (continued)
| Years Ended December 31, | ||||
|---|---|---|---|---|
| 2025 · 2024 | ||||
| Supplemental Cash Flow Information: | ||||
| Cash paid for interest | $5,607 | $1,204 | ||
| Cash paid for income taxes | - | - | ||
| Non-Cash Financing Activities | ||||
| Issuance of 200 shares of common stock in connection with a licensing agreement which had previously been recorded as a due to licensor | $ | - | $189,000 | |
| Right-of-use asset obtained in exchange for financing lease liability | $ | - | $11,804 | |
| Financing lease liability | - | (11,804) | ||
| Net | $ | - | $ | - |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.